Clinical progression in Parkinson disease and the neurobiology of axons

Cited by (1,001)

Items 401–500 of 1,001

1. From Synaptic Protein to Prion: The Long and Controversial Journey of α-Synuclein
   Antonio Heras‐Garvin, Nadia Stefanova · 2020 · Frontiers in Synaptic Neuroscience
2. Sensogenomics of music and Alzheimer’s disease: An interdisciplinary view from neuroscience, transcriptomics, and epigenomics
   Laura Navarro, Alberto Gómez‐Carballa, Sara Pischedda, Julián Montoto-Louzao, Sandra Viz-Lasheras, Alba Camino‐Mera, Thomas Hinault, Federico Martinón‐Torres, Antonio Salas · 2023 · Frontiers in Aging Neuroscience
3. Longitudinal decline in striatal dopamine transporter binding in Parkinson’s disease: associations with apathy and anhedonia
   H. Costello, Y. Yamamori, S. Reeves, A. Schrag, R. Howard, J. Roiser · 2022 · Journal of Neurology Neurosurgery & Psychiatry
4. Longitudinal brain volumetric changes and their predictive effects on cognition among cognitively asymptomatic patients with Parkinson's disease
   Ming‐Ching Wen, Aloysius Yue Tat Ng, Russell Jude Chander, Wing Lok Au, Louis Tan, Nagaendran Kandiah · 2015 · Parkinsonism & Related Disorders
5. Modeling Parkinson’s disease and treatment complications in rodents: Potentials and pitfalls of the current options
   Veronica Francardo · 2017 · Behavioural Brain Research
6. Prediction of mechanistic subtypes of Parkinson’s using patient-derived stem cell models
   Karishma D’Sa, James R. Evans, Gurvir S. Virdi, Giulia Vecchi, Alexander Adam, Ottavia Bertolli, James Fleming, Hojong Chang, Craig Leighton, Mathew H. Horrocks et al. · 2023 · Nature Machine Intelligence
7. Impact of Physical Activity on Cellular Metabolism Across Both Neurodegenerative and General Neurological Conditions: A Narrative Review
   Vicente Javier Clemente‐Suárez, Alejandro Rubio-Zarapuz, Pedro Belinchón-deMiguel, Ana Isabel Beltrán-Velasco, Alexandra Martín-Rodríguez, José Francisco Tornero-Aguilera · 2024 · Cells
8. Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection
   Ryo Kikuoka, Ikuko Miyazaki, Natsuki K. Kubota, Megumi Maeda, Daiki Kagawa, Masaaki Moriyama, Asuka Sato, Shinki Murakami, Yoshihisa Kitamura, Toshiaki Sendo et al. · 2020 · Scientific Reports
9. Parkinson’s Disease Detection Using Ensemble Architecture from MR Images
   Tahjid Ashfaque Mostafa, Irene Cheng · 2020 · IEEE International Conference on Bioinformatics and Bioengineering (BIBE)
10. Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson’s disease: removing axonal debris
    Ingrid Moráles, Ricardo Puertas‐Avendaño, Alberto Sánchez, Adrian Perez‐Barreto, Clara Rodriguez‐Sabate, Manuel Rodrı́guez · 2021 · Translational Neurodegeneration
11. Evidence of oligodendrogliosis in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced Parkinsonism
    Valentina Annese, Carlos Barcia, Francisco Ros‐Bernal, A. Gómez, Carmen María Brugarolas Ros, Vicente de Pablos, Emiliano Fernández‐Villalba, Maria Egle De Stefano, María Trinidad Herrero · 2012 · Neuropathology and Applied Neurobiology
12. Plasma Prolidase Activity and Oxidative Stress in Patients with Parkinson’s Disease
    Akhilesh Kumar Verma, Janak Raj, Vivek Sharma, Tej Bali Singh, Shalabh Srivastava, Ragini Srivastava · 2015 · Parkinson s Disease
13. Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
    Choi, Hye Kyu, Chen, Meizi, Goldston, Li Ling, Lee, Ki-Bum · 2024 · Nano Convergence
14. How neurons maintain their axons long-term: an integrated view of axon biology and pathology
    Gaynor Ann Smith, Sean T. Sweeney, Cahir J. O’Kane, Andreas Prokop · 2023 · Frontiers in Neuroscience
15. Protein mimetic 2D FAST rescues alpha synuclein aggregation mediated early and post disease Parkinson’s phenotypes
    Nicholas H. Stillman, Johnson A. Joseph, Jemil Ahmed, Charles Zuwu Baysah, Ryan A. Dohoney, Tyler D. Ball, Alexandra G. Thomas, Tessa C. Fitch, Courtney M. Donnelly, Sunil Kumar · 2024 · Nature Communications
16. Systems pharmacology based approach to investigate the in-vivo therapeutic efficacy of Albizia lebbeck (L.) in experimental model of Parkinson’s disease
    Uzma Saleem, Zohaib Raza, Fareeha Anwar, Zunera Chaudary, Bashir Ahmad · 2019 · BMC Complementary and Alternative Medicine
17. HSPA9/Mortalin mediates axo-protection and modulates mitochondrial dynamics in neurons
    Cécile A. Ferre, Anne Thouard, Alexandre Bétourné, Anne-Louise Le Dorze, Pascale Belenguer, Marie‐Christine Miquel, Jean‐Michel Peyrin, Daniel Gonzalez‐Dunia, Marion Szelechowski · 2021 · Scientific Reports
18. Low molecular weight polysialic acid prevents lipopolysaccharide‐induced inflammatory dopaminergic neurodegeneration in humanized SIGLEC11 transgenic mice
    Huan Liao, Jonas Winkler, Jannis Wißfeld, Anahita Shahraz, Christine Klaus, Harald Neumann · 2021 · Glia
19. Neuronal biomarkers of Parkinson's disease are present in healthy aging
    Juanli Zhang, Mina Jamshidi Idaji, Arno Villringer, Vadim V. Nikulin · 2021 · NeuroImage
20. Synaptic proteostasis in Parkinson's disease
    Eliana Nachman, Patrik Verstreken · 2021 · Current Opinion in Neurobiology
21. Biomaterial and tissue-engineering strategies for the treatment of brain neurodegeneration
    Bridget Martinez, Philip V. Peplow · 2022 · Neural Regeneration Research
22. A novel synthetic peptide SVHRSP attenuates dopaminergic neurodegeneration by inhibiting NADPH oxidase-mediated neuroinflammation in experimental models of Parkinson's disease
    Xiaomeng Zhang, Dezhen Tu, Sheng Li, Na Li, Donglai Li, Yun Gao, Lu Tian, Jianing Liu, Xuan Zhang, Jau‐Shyong Hong et al. · 2022 · Free Radical Biology and Medicine
23. Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson’s Disease
    Irene Sanchez-Mirasierra, Saurav Ghimire, Sergio Hernández-Díaz, Sandra‐Fausia Soukup · 2022 · Frontiers in Cell and Developmental Biology
24. Knowing Me, Knowing You: Can a Knowledge of Risk Factors for Alzheimer's Disease Prove Useful in Understanding the Pathogenesis of Parkinson's Disease?
    Greg Trevor Sutherland, Gerhard A. Siebert, Jillian J. Kril, George D. Mellick · 2011 · Journal of Alzheimer s Disease
25. Small Peptide Inhibitor of JNK3 Protects Dopaminergic Neurons from MPTP Induced Injury via Inhibiting the ASK1-JNK3 Signaling Pathway
    Jing Pan, Hui Li, Bei Zhang, Ran Xiong, Yu Zhang, Wenyan Kang, Wei Chen, Zongbo Zhao, Shengdi Chen · 2015 · PLoS ONE
26. Teaghrelin Protects SH-SY5Y Cells against MPP+-Induced Neurotoxicity through Activation of AMPK/SIRT1/PGC-1α and ERK1/2 Pathways
    Cian‐Fen Jhuo, Sheng‐Kuo Hsieh, Chun‐Jung Chen, Wen‐Ying Chen, Jason T. C. Tzen · 2020 · Nutrients
27. Exploring the connection between the gut microbiome and parkinson's disease symptom progression and pathology: implications for supplementary treatment options
    Chan, Dennis G., Ventura, Katelyn, Villeneuve, Ally, Du Bois, Paul, Holahan, Matthew R. · 2022 · Journal of Parkinson's Disease
28. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson’s disease using neuromelanin-sensitive MRI: Replication in two cohorts
    Kristy Hwang, Jason A. Langley, Richa Tripathi, Xiaoping Philip Hu, Daniel E. Huddleston · 2023 · PLoS ONE
29. Cortical Implications of Advancing Age and Disease Duration in Parkinson’s Disease Patients with Postural Instability and Gait Dysfunction
    Joshua Herb, Swati Rane Levendovszky, David Alan Isaacs, Nelleke Corine van Wouwe, Olivia C. Roman, Bennett A. Landman, Benoît M. Dawant, Peter Hedera, David Harold Zald, Joseph Samir Neimat et al. · 2016 · Journal of Parkinson s Disease
30. Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson’s Disease?
    Christian Ulrich von Linstow, Merritt DeLano-Taylor, Jeffrey H. Kordower, Patrik Brundin · 2020 · Journal of Parkinson s Disease
31. Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson’s disease through mitochondrial dysfunction
    Chung‐Yang Kao, Mafei Xu, Leiming Wang, Shih‐Chieh Lin, Hui-Ju Lee, Lita Duraine, Hugo Jozef Bellen, David S. Goldstein, Sophia Y. Tsai, Ming‐Jer Tsai · 2020 · PLoS Genetics
32. Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders
    Dharmendra Kumar Khatri, Amey Kadbhane, Monica Patel, Shweta Nene, Srividya Atmakuri, Saurabh Srivastava, Shashi Bala Singh · 2021 · Current Research in Pharmacology and Drug Discovery
33. Experimental deep brain stimulation in rodent models of movement disorders
    Susanne Knörr, Thomas Musacchio, Raik Paulat, Cordula Matthies, Heinz Endres, Nikolaus Wenger, Christoph Harms, Chi Wang Ip · 2021 · Experimental Neurology
34. Focused Ultrasound Promotes the Delivery of Gastrodin and Enhances the Protective Effect on Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease
    Yuhong Wang, Kaixuan Luo, Junrui Li, Ye-Hui Liao, Chengde Liao, Wen‐Shiang Chen, Mo-Xian Chen, Lijuan Ao · 2022 · Frontiers in Cellular Neuroscience
35. Targeting dopamine transporter to ameliorate cognitive deficits in Alzheimer's disease
    Ammara Shaikh, Fairus Ahmad, Seong Lin Teoh, Jaya Kumar, Mohamad Fairuz Yahaya · 2023 · Frontiers in Cellular Neuroscience
36. A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells
    Yahaira Naaldijk, Belén Fernández, Rachel Fasiczka, Elena Fdez, Coline Leghay, Ioana M. Croitoru, John B. Kwok, Yanisse Boulesnane, Amélie Vizeneux, Eugénie Mutez et al. · 2024 · npj Parkinson s Disease
37. Unlocking the Epigenetic Symphony: Histone Acetylation’s Impact on Neurobehavioral Change in Neurodegenerative Disorders
    Balapal S. Basavarajappa, Shivakumar Subbanna · 2024 · Epigenomics
38. Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson’s Disease
    Anelya Kh. Alieva, Elena V. Filatova, Anna A. Kolacheva, Margarita M. Rudenok, Petr A. Slominsky, Michael V. Ugrumov, Maria I. Shadrina · 2016 · Molecular Neurobiology
39. Identification of biomarkers associated with Parkinson’s disease by gene expression profiling studies and bioinformatics analysis
    Marios G. Krokidis · 2019 · AIMS neuroscience
40. Linalool, a Fragrance Compound in Plants, Protects Dopaminergic Neurons and Improves Motor Function and Skeletal Muscle Strength in Experimental Models of Parkinson’s Disease
    Wan‐Hsuan Chang, Hung‐Te Hsu, Chih‐Cheng Lin, Li‐Mei An, Chien‐Hsing Lee, Horng‐Huey Ko, Chih‐Lung Lin, Yi‐Ching Lo · 2024 · International Journal of Molecular Sciences
41. Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson’s Disease
    D. Luke Fischer, Sara E. Gombash, Christopher J. Kemp, Fredric P. Manfredsson, Nicole K. Polinski, Megan F. Duffy, Caryl E. Sortwell · 2015 · Methods in molecular biology
42. Auraptene Mitigates Parkinson’s Disease-Like Behavior by Protecting Inhibition of Mitochondrial Respiration and Scavenging Reactive Oxygen Species
    Yunseon Jang, Hyosun Choo, Min Joung Lee, Jeongsu Han, Soo‐Jeong Kim, Xianshu Ju, Jianchen Cui, Yu Lim Lee, Min Jeong Ryu, Eungseok Oh et al. · 2019 · International Journal of Molecular Sciences
43. Enhanced Susceptibility of PINK1 Knockout Rats to α-Synuclein Fibrils
    Rose B. Creed, Matthew S. Goldberg · 2020 · Neuroscience
44. Presynaptic accumulation of α-synuclein causes synaptopathy and progressive neurodegeneration in Drosophila
    Jéssika Cristina Bridi, Erika Bereczki, Saffron K. Smith, Gonçalo M. Poças, Benjamin Kottler, Pedro Manuel Dias Neto Domingos, Christopher J. H. Elliott, Dag Aarsland, Frank Hirth · 2021 · Brain Communications
45. Imaging of the dopamine system with focus on pharmacological MRI and neuromelanin imaging
    Liesbeth Reneman, Marieke van der Pluijm, Anouk Schrantee, Elsmarieke van de Giessen · 2021 · European Journal of Radiology
46. Disentangling nigral and putaminal contribution to motor impairment and levodopa response in Parkinson’s disease
    Nils Schröter, Michel Rijntjes, Horst Urbach, Cornelius Weiller, Martin Treppner, Elias Kellner, Wolfgang H. Jost, Bastian Sajonz, Marco Reisert, Jonas A. Hosp et al. · 2022 · npj Parkinson s Disease
47. Protective effects of DA-9805 on dopaminergic neurons against 6-hydroxydopamine-induced neurotoxicity in the models of Parkinson’s disease
    Hyeyoon Eo, Youngji Kwon, Eugene Huh, Yeomoon Sim, Jin Gyu Choi, Jin Seok Jeong, Xiao Fei Du, Hye Yeon Soh, Seon-Pyo Hong, Youngmi Kim Pak et al. · 2019 · Biomedicine & Pharmacotherapy
48. A standardized randomized 6-month aerobic exercise-training down-regulated pro-inflammatory genes, but up-regulated anti-inflammatory, neuron survival and axon growth-related genes
    Osigbemhe Iyalomhe, Yuanxiu Chen, Joanne S. Allard, Oyonumo E. Ntekim, Shereé M. Johnson, Vernon Bond, David S. Goerlitz, James Li, Thomas Olabode Obisesan · 2015 · Experimental Gerontology
49. Neurodegeneration in Parkinson disease
    Walter Schulz‐Schaeffer · 2012 · Neurology
50. Spatiotemporal patterns of brain iron-oxygen metabolism in patients with Parkinson’s disease
    Su Yan, Jun Lu, Yuanhao Li, Junghun Cho, Shun Zhang, Wenzhen Zhu, Yi Wang · 2023 · European Radiology
51. Fluorogenic Chemical Probes for Wash-free Imaging of Cell Membrane Damage in Ferroptosis, Necrosis, and Axon Injury
    Philipp Mauker, Daniela Beckmann, Annabel Kitowski, Constanze Heise, Chantal Wientjens, Andrew J. Davidson, Simone Wanderoy, Gabin Fabre, Angelika Bettina Harbauer, Will Wood et al. · 2024 · Journal of the American Chemical Society
52. A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects
    Yan Shen, Jinsha Huang, Ling Liu, Xiaoyun Xu, Chao Han, Guoxin Zhang, Haiyang Jiang, Jie Li, Zhicheng Lin, Nian Xiong et al. · 2016 · Frontiers in Aging Neuroscience
53. Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson’s Disease
    Catalina Requejo, José Ángel Ruíz-Ortega, Hodei Cepeda, A. Sharma, Hari Shanker Sharma, Asya Ozkızılcık, Z. Ryan Tian, Herbert Moessler, Luisa Ugedo, José Vicente Lafuente · 2017 · Molecular Neurobiology
54. Autophagy at synapses in neurodegenerative diseases
    Wongyoung Lee, Sung Hyun Kim · 2019 · Archives of Pharmacal Research
55. Tears – More to Them Than Meets the Eye: Why Tears Are A Good Source of Biomarkers in Parkinson'S Disease
    Maria C. Edman, Srikanth Reddy Janga, Shruti Singh Kakan, Curtis T. Okamoto, Daniel Freire, Danielle Feigenbaum, Mark Lew, Sarah F. Hamm‐Alvarez · 2020 · Biomarkers in Medicine
56. Female mice are resilient to age-related decline of substantia nigra dopamine neuron firing parameters
    Rebecca Dean Howell, Sergio Domínguez-López, Sarah R. Ocañas, Willard M. Freeman, Michael J. Beckstead · 2020 · Neurobiology of Aging
57. Perspective: Treatment for Disease Modification in Chronic Neurodegeneration
    Thomas H. Müller, Bernhard K. Mueller, Peter Franz Riederer · 2021 · Cells
58. Exploring the multifactorial aspects of Gut Microbiome in Parkinson’s Disease
    Sujith Pavan, Arvind Prabhu, Sankar Prasad Gorthi, Bhabatosh Das, Ankur Mutreja, Vignesh Shetty, Thandavarayan Ramamurthy, Mamatha Ballal · 2022 · Folia Microbiologica
59. Genetic Evidence for Endolysosomal Dysfunction in Parkinson’s Disease: A Critical Overview
    Vidal Yahya, Alessio Di Fonzo, Edoardo Monfrini · 2023 · International Journal of Molecular Sciences
60. An adaptive weighted attention-enhanced deep convolutional neural network for classification of MRI images of Parkinson's disease
    Xinchun Cui, Ningning Chen, Chao Zhao, Jianlong Li, Xiangwei Zheng, Caixia Liu, Jiahu Yang, Xiuli Li, Chao Yu, Jinxing Liu et al. · 2023 · Journal of Neuroscience Methods
61. Manganese‐ and 1‐methyl‐4‐phenylpyridinium‐induced neurotoxicity display differences in morphological, electrophysiological and genome‐wide alterations: implications for idiopathic Parkinson's disease
    Rajeswara Babu Mythri, Narayana Reddy Raghunath, S. Narwade, M. D. Pandareesh, K.R. Sabitha, Mohamad Aiyaz, Bipin Chand, Manas Sule, Krittika Ghosh, Senthil Kumar et al. · 2017 · Journal of Neurochemistry
62. Vocal Biomarkers for Parkinson’s Disease Classification Using Audio Spectrogram Transformers
    Nuwan Madusanka, Byeong-Il Lee · 2024 · Journal of Voice
63. Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease
    Gerard W. O’Keeffe, Shane Vincent Hegarty, Aideen M. Sullivan · 2017 · Neuronal Signaling
64. Small Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic Factor Receptors for the Treatment of Neurodegeneration
    Yulia A. Sidorova, Märt Saarma · 2020 · International Journal of Molecular Sciences
65. Patients with scans without evidence of dopaminergic deficit (SWEDD) do not have early Parkinson’s disease: Analysis of the PPMI data
    Jeong Won Lee, Yoo Sung Song, Hyeyun Kim, Bon D. Ku, Won Woo Lee · 2021 · PLoS ONE
66. Progressive microstructural alterations in subcortical nuclei in Parkinson's disease: A diffusion magnetic resonance imaging study
    Xueqin Bai, Cheng Zhou, Tao Guo, Xiaojun Guan, Jingjing Wu, Xiaocao Liu, Ting Gao, Luyan Gu, Min Xuan, Quanquan Gu et al. · 2021 · Parkinsonism & Related Disorders
67. Automatic detection of neuromelanin and iron in the midbrain nuclei using a magnetic resonance imaging ‐based brain template
    Zhijia Jin, Ying Wang, Mojtaba Jokar, Yan Li, Zenghui Cheng, Yu Liu, Rongbiao Tang, Xiaofeng Shi, Youmin Zhang, Jihua Min et al. · 2022 · Human Brain Mapping
68. Detection and assessment of alpha-synuclein in Parkinson disease
    Hsien-Hao Tsao, Chung‐Guei Huang, Yih‐Ru Wu · 2022 · Neurochemistry International
69. Mitochondrial behavior when things go wrong in the axon
    Victorio M. Pozo Devoto, Isaac G. Onyango, Gorazd Bernard Stokin · 2022 · Frontiers in Cellular Neuroscience
70. Intracellular signalling pathways in dopamine cell death and axonal degeneration
    Robert E. Burke · 2010 · Progress in brain research
71. Mitochondrial health maintenance in axons
    Angelika Bettina Harbauer · 2017 · Biochemical Society Transactions
72. Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease
    Koji Kasanuki, Michael G. Heckman, Nancy N. Diehl, Melissa Erin Murray, Shunsuke Koga, Alexandra I. Soto, Owen A. Ross, Dennis W. Dickson · 2017 · Movement Disorders
73. Identification of altered microRNAs in serum of a mouse model of Parkinson’s disease
    Héctor Rosas-Hernández, Srinivasulu Chigurupati, James B. Raymick, Bonnie L. Robinson, Elvis Cuevas, Joseph P. Hanig, Sumit Sarkar · 2018 · Neuroscience Letters
74. Blood biomarker for Parkinson disease: peptoids
    Umar Yazdani, Sayed Zaman, Linda Susan Hynan, Lamar Brown, Richard B. Dewey, David R. Karp, Dwight C. German · 2016 · npj Parkinson s Disease
75. Systemic inflammation accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human alpha synuclein
    Mariangela Massaro Cenere, Marta Tiberi, Emanuela Paldino, Sebastian Luca D’Addario, Mauro Federici, Cecilia Giacomet, Debora Cutuli, Alessandro Matteocci, Francesca Cossa, Beatrice Zarrilli et al. · 2024 · npj Parkinson s Disease
76. Increased glutamate transmission onto dorsal striatum spiny projection neurons in Pink1 knockout rats
    Rose B. Creed, Rosalinda C. Roberts, Charlene B. Farmer, Lori L. McMahon, Matthew S. Goldberg · 2020 · Neurobiology of Disease
77. Proteome-Wide Profiling of Cellular Targets Modified by Dopamine Metabolites Using a Bio-Orthogonally Functionalized Catecholamine
    Alexander K. Hurben, Luke N. Erber, Natalia Y. Tretyakova, Todd M. Doran · 2021 · ACS Chemical Biology
78. Designing nanoformulation for the nose‐to‐brain delivery in Parkinson's disease: Advancements and barrier
    Pallavi Kiran, Sujit Kumar Debnath, Suditi Neekhra, Vaishali Satyajeet Pawar, Amreen Khan, Faith Dias, Shubham Pallod, Rohit Srivastava · 2021 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
79. Similarities, differences and overlaps between frailty and Parkinson's disease
    Junya Ebina, Satoru Ebihara, Osamu Kano · 2022 · Geriatrics and gerontology international/Geriatrics & gerontology international
80. Impact of Nutrition, Microbiota Transplant and Weight Loss Surgery on Dopaminergic Alterations in Parkinson’s Disease and Obesity
    Sevag Hamamah, András Sándor Hajnal, Mihai Covașă · 2022 · International Journal of Molecular Sciences
81. Sex and Age Differences in a Progressive Synucleinopathy Mouse Model
    Jérôme Lamontagne‐Proulx, Katherine Coulombe, Marc Morissette, Marie Rieux, Frédéric Calon, Thérèse Di Paolo, Denis Soulet · 2023 · Biomolecules
82. Proof-of-Principle Study of Inflammasome Signaling Proteins as Diagnostic Biomarkers of the Inflammatory Response in Parkinson’s Disease
    Erika d. l. R. M. Cabrera Ranaldi, Karen Nuytemans, Anisley Martinez, Corneliu C. Luca, Robert W. Keane, Juan Pablo de Rivero Vaccari · 2023 · Pharmaceuticals
83. Parkinson's disease: Are gut microbes involved?
    Abass Olawale Omotosho, Yusuf Amuda Tajudeen, Habeebullah Jayeola Oladipo, Sodiq Inaolaji Yusuff, Muritala Abdulkadir, Abdulbasit Opeyemi Muili, Oluwaseyi Muyiwa Egbewande, Rashidat Onyinoyi Yusuf, Zaccheaus Oluwaseun Faniran, Abdullateef Opeyemi Afolabi et al. · 2023 · Brain and Behavior
84. Developmental exposure to the Parkinson’s disease-associated organochlorine pesticide dieldrin alters dopamine neurotransmission in α-synuclein pre-formed fibril (PFF)-injected mice
    S. Boyd, Nathan C. Kuhn, Joseph R. Patterson, Anna C. Stoll, Sydney A Zimmerman, Mason R. Kolanowski, Joseph J. Neubecker, Kelvin C. Luk, Eric S. Ramsson, Caryl E. Sortwell et al. · 2023 · Toxicological Sciences
85. Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease
    Makoto Naoi, Wakako Maruyama, Masayo Shamoto‐Nagai, Peter Franz Riederer · 2024 · Journal of Neural Transmission
86. Interaction between α-synuclein and tau in Parkinson's disease
    K. A. Jellinger · 2010 · Experimental Neurology
87. Neurobehavioral Anomalies in the Pitx3/ak Murine Model of Parkinson’s Disease and MPTP
    Mohammed Filali, Robert Lalonde · 2015 · Behavior Genetics
88. Glial cell line-derived neurotrophic factor family ligands and their therapeutic potential
    Yulia A. Sidorova, Märt Saarma · 2016 · Molecular Biology
89. The Convergence of Dopamine and α-Synuclein: Implications for Parkinson’s Disease
    Danielle E. Mor, Harry Ischiropoulos · 2018 · Journal of Experimental Neuroscience
90. Failure in a population: Tauopathy disrupts homeostatic set-points in emergent dynamics despite stability in the constituent neurons
    James N. McGregor, Clayton A. Farris, Sahara Ensley, Aidan M Schneider, Leandro J. Fosque, Chao Wang, Elizabeth I. Tilden, Yuqi Liu, Jianhong Tu, Halla Elmore et al. · 2024 · Neuron
91. Peripheral blood immune cells from individuals with Parkinson's disease or inflammatory bowel disease share deficits in iron storage and transport that are modulated by non-steroidal anti-inflammatory drugs
    MacKenzie L. Bolen, Beatriz Nuñes Gomes, Blake Gill, Kelly B. Menees, Hannah A. Staley, Janna E. Jernigan, Nikolaus R. McFarland, Ellen M. Zimmermann, Christopher E. Forsmark, Malú G. Tansey · 2025 · Neurobiology of Disease
92. Human Amniotic Epithelial Cells Alleviate a Mouse Model of Parkinson’s Disease Mainly by Neuroprotective, Anti-Oxidative and Anti-Inflammatory Factors
    Jiaofei Zhang, Hui Li, Hao Yang, Jianhua Lin, You Wang, Qianjun Zhang, Wei‐Qiang Gao, Huiming Xu · 2020 · Journal of Neuroimmune Pharmacology
93. CDNF and MANF in the brain dopamine system and their potential as treatment for Parkinson’s disease
    Emmi Pakarinen, Päivi Lindholm · 2023 · Frontiers in Psychiatry
94. Vesicular monoamine transporter (VMAT) regional expression and roles in pathological conditions
    Malik Alwindi, Ariege Bizanti · 2023 · Heliyon
95. The formation of biodegradable micelles from a therapeutic initiator for enzyme-mediated drug delivery
    Mthulisi Khuphe, Algy Kazlauciunas, Martin Huscroft, Paul D. Thornton · 2014 · Chemical Communications
96. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies
    Javier Fernández‐Ruíz, María Gómez‐Ruíz, Concepción García, Mariluz Hernández, José Antonio Ramos · 2017 · Methods in enzymology on CD-ROM/Methods in enzymology
97. Earliest Mechanisms of Dopaminergic Neurons Sufferance in a Novel Slow Progressing Ex Vivo Model of Parkinson Disease in Rat Organotypic Cultures of Substantia Nigra
    Matteo Dal Ben, Rosario Bongiovanni, Simone Tuniz, Emanuela Fioriti, Claudio Tiribelli, Rita Moretti, Silvia Gazzin · 2019 · International Journal of Molecular Sciences
98. Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain
    Junchao Tong, Yoshiaki Furukawa, Allan L. Sherwin, Oleh Hornykiewicz, Stephen J. Kish · 2010 · Neurobiology of Disease
99. Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with α-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson’s Model in Rats
    Akanksha Mishra, Sairam Krishnamurthy · 2019 · Neurotoxicity Research
100. Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson’s Disease
     Hendrik Theis, Nicola Pavese, Irena Rektorová, Thilo van Eimeren · 2024 · Journal of Parkinson s Disease